{"id":6767,"date":"2024-10-15T15:03:09","date_gmt":"2024-10-15T07:03:09","guid":{"rendered":"https:\/\/flcube.com\/?p=6767"},"modified":"2024-10-15T15:03:12","modified_gmt":"2024-10-15T07:03:12","slug":"novo-nordisk-expands-legal-campaign-to-50-cases-against-semaglutide-compounders","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=6767","title":{"rendered":"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders"},"content":{"rendered":"\n

Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing a lawsuit against another semaglutide compounder, increasing the total number of such cases to 50. The Danish pharmaceutical giant, along with Eli Lilly (NYSE: LLY<\/a>), has initiated legal campaigns targeting medical spas, weight loss clinics, and compounding pharmacies that market their own versions of the popular weight loss and diabetes drugs.<\/p>\n\n\n\n

In a recent development favorable to compounders, the FDA indicated it would reconsider the removal of Lilly\u2019s tirzepatide from its national shortage list, potentially allowing some compounders to sell their versions while the agency evaluates. Compounding is permitted when a drug must be modified to suit a patient’s needs or during shortages.<\/p>\n\n\n\n

Novo Nordisk continues to report “limited availability” for one dose of its weight loss drug Wegovy, as per the FDA\u2019s shortage database. However, the company persists in its legal action against compounders, arguing that deceptive marketing could mislead patients into believing the compounded products are FDA-approved or genuine Novo products.<\/p>\n\n\n\n

During September and October, Novo Nordisk filed 18 new lawsuits against compounders. The most recent lawsuit targets Advanced Vitality HRT, a medical clinic based in Cincinnati. Advanced Vitality was not available for immediate comment.<\/p>\n\n\n\n

“As the FDA has cautioned, unapproved compounded \u2018semaglutide\u2019 drugs do not have the same safety, quality, and effectiveness assurances as Novo Nordisk\u2019s FDA-approved semaglutide medicines, and patients should not use a compounded drug if an approved drug is available,” a Novo Nordisk spokesperson stated on Monday.<\/p>\n\n\n\n

The company noted an increase in adverse event reports following the rise in the use of compounded semaglutide products. The spokesperson declared that Novo will “continue to pursue legal action against other entities engaged in similar conduct.”- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing…<\/p>\n","protected":false},"author":1,"featured_media":6768,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[61],"tags":[39,148,911,860,86],"class_list":["post-6767","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-legal-ip","tag-diabetes","tag-novo-nordisk","tag-nyse-lly","tag-nyse-nvo","tag-obesity"],"yoast_head":"\nNovo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing a lawsuit against another semaglutide compounder, increasing the total number of such cases to 50. The Danish pharmaceutical giant, along with Eli Lilly (NYSE: LLY), has initiated legal campaigns targeting medical spas, weight loss clinics, and compounding pharmacies that market their own versions of the popular weight loss and diabetes drugs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=6767\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=6767\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-15T07:03:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-15T07:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"550\" \/>\n\t<meta property=\"og:image:height\" content=\"309\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders\",\"datePublished\":\"2024-10-15T07:03:09+00:00\",\"dateModified\":\"2024-10-15T07:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767\"},\"wordCount\":300,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg\",\"keywords\":[\"Diabetes\",\"Novo Nordisk\",\"NYSE: LLY\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=6767#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=6767\",\"name\":\"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg\",\"datePublished\":\"2024-10-15T07:03:09+00:00\",\"dateModified\":\"2024-10-15T07:03:12+00:00\",\"description\":\"Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing a lawsuit against another semaglutide compounder, increasing the total number of such cases to 50. The Danish pharmaceutical giant, along with Eli Lilly (NYSE: LLY), has initiated legal campaigns targeting medical spas, weight loss clinics, and compounding pharmacies that market their own versions of the popular weight loss and diabetes drugs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=6767\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg\",\"width\":550,\"height\":309,\"caption\":\"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=6767#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders - Insight, China's Pharmaceutical Industry","description":"Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing a lawsuit against another semaglutide compounder, increasing the total number of such cases to 50. The Danish pharmaceutical giant, along with Eli Lilly (NYSE: LLY), has initiated legal campaigns targeting medical spas, weight loss clinics, and compounding pharmacies that market their own versions of the popular weight loss and diabetes drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=6767","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=6767","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-15T07:03:09+00:00","article_modified_time":"2024-10-15T07:03:12+00:00","og_image":[{"width":550,"height":309,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=6767#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=6767"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders","datePublished":"2024-10-15T07:03:09+00:00","dateModified":"2024-10-15T07:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=6767"},"wordCount":300,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=6767#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg","keywords":["Diabetes","Novo Nordisk","NYSE: LLY","NYSE: NVO","Obesity"],"articleSection":["Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=6767#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=6767","url":"https:\/\/flcube.com\/?p=6767","name":"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=6767#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=6767#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg","datePublished":"2024-10-15T07:03:09+00:00","dateModified":"2024-10-15T07:03:12+00:00","description":"Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing a lawsuit against another semaglutide compounder, increasing the total number of such cases to 50. The Danish pharmaceutical giant, along with Eli Lilly (NYSE: LLY), has initiated legal campaigns targeting medical spas, weight loss clinics, and compounding pharmacies that market their own versions of the popular weight loss and diabetes drugs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=6767#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=6767"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=6767#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg","width":550,"height":309,"caption":"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=6767#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0146bf4ba42b6f8aac1dcf4c23323b1b.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/6767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6767"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/6767\/revisions"}],"predecessor-version":[{"id":6769,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/6767\/revisions\/6769"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/6768"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}